Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.63 |
| ▸ | MMP13 | P45452 | 6/20 | 0.63 |
| ▸ | MMP9 | P14780 | 5/20 | 0.63 |
| ▸ | MMP8 | P22894 | 5/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802971 | 0.92 | MMP2 (0.73) | MMP2MMP13MMP9MMP8CHEK2 | |
| SCHEMBL2313533 | 0.81 | CHEK2 (0.54) | CHEK2 | |
| SCHEMBL2808586 | 0.81 | MMP2 (0.62) | MMP2MMP13MMP9MMP8CHEK2 | |
| SCHEMBL2805873 | 0.81 | CHEK2 (0.55) | MMP2MMP13MMP9MMP8CHEK2 | |
| SCHEMBL2805951 | 0.79 | CHEK2 (0.57) | MMP2MMP13MMP9MMP8CHEK2 | |
| SCHEMBL2804495 | 0.79 | CHEK2 (0.56) | MMP2MMP13MMP9MMP8CHEK2 | |
| SCHEMBL2802895 | 0.76 | SCD (0.56) | CHEK2ALDH1A1HPGDPOLBRECQL | |
| SCHEMBL21045176 | 0.74 | RAB9A (0.60) | ALDH1A1HSD17B10TP53POLBRECQL | |
| SCHEMBL2809774 | 0.73 | KDR (0.57) | CHEK2ALDH1A1HPGD | |
| SCHEMBL21018492 | 0.73 | EGFR (0.65) | MMP2MMP13MMP9MMP8TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | claimed |
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | CYP3A43, CYP11B1, CYP11B2 | MMP2 3953/4885MMP13 4013/4885MMP9 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.